Fiscal Year End | Company Status | Exempt Flag |
February 29 | Delist | N |
|
|
|
|
|
Incorporation Locations |
Inc. Date | Expiry Date | Country | Region | Description |
1/Feb/2002 | 27/Mar/2023 | Canada | Quebec | |
|
|
Exchange Filing Office |
Location |
(not available) |
|
| |
Business Type(s) |
Primary/Secondary | Business Type | Details |
Primary
| *Research and Development in the Physical, Engineering and Life Sciences
| News Release April 29, 2015-Acasti is an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, in particular abnormalities in blood lipids, also known as dyslipidemia. Because krill feeds on phytoplankton (diatoms and dinoflagellates), it is a major source of phospholipids and polyunsaturated fatty acids ("PUFAs"), mainly eicosapentaenoic acid ("EPA") and docosahexaenoic acid ("DHA"), which are two types of omega-3 fatty acids well known to be beneficial for human health. CaPre(R), currently Acasti's only prescription drug candidate, is a highly purified omega-3 phospholipid concentrate derived from krill oil and is being developed to help prevent and treat hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream.
|
|
|
Securities |
Symbol | Security Name | Market | Status |
*ACST | *Acasti Pharma Inc. | TSX Venture | DELIST |
*ACST | *Acasti Pharma Inc old | TSX Venture | DELIST |
*APO | *Acasti Pharma Inc old | TSX Venture | DELIST |
*APO | *Acasti Pharma Inc. Old | TSX Venture | DELIST |
*APO.RT | *Acasti Pharma Inc rt ex 14sept2011 | TSX Venture | DELIST |
|
|
Name History | From | To |
*Acasti Pharma Inc. | 1/Feb/2002 | 27/Mar/2023 |
|
|
Company Facts Reconciliation |
Subject | Date Returned |
Spring 2015 CFR | Not Received |
|
|
|
|